Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

800 TCR

Next Previous
X
Search
Drug Profile

800 TCR

Alternative Names: 800-TCR; anti-HERV-E TCR - T-Cure Bioscience; TCR-800

Latest Information Update: 02 Feb 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator T-Cure
  • Developer Immunotech Biopharm; National Heart, Lung and Blood Institute
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Renal cell carcinoma

Most Recent Events

  • 28 Jan 2024 Pharmacodynamics data from a preclinical trial in Renal cell carcinoma released by T-Cure BioScience
  • 25 Jan 2024 Efficacy and adverse events data from a phase I trial in Renal cell carcinoma presented at the 2024 Genitourinary Cancers Symposium (ASCO-GeCS-2024)
  • 11 Jan 2023 800 TCR is still in phase-I trial for Renal cell carcinoma (Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT03354390) (T-cure pipeline; January 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top